Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:03AM EST. Market open.
| Previous close | 74.50 |
| Open | 75.60 |
| Bid | 74.76 x 1300 |
| Ask | 75.20 x 800 |
| Day's range | 74.66 - 76.10 |
| 52-week range | 71.88 - 120.27 |
| Volume | |
| Avg. volume | 882,174 |
| Market cap | 7.108B |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | 16.49 |
| EPS (TTM) | 4.54 |
| Earnings date | 11 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 120.77 |
- Simply Wall St.
Here's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Is An Interesting Stock
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
- Motley Fool
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Shares of biopharma Neurocrine Biosciences (NASDAQ: NBIX) were down 9.8% in Tuesday's late trading following a disappointing third-quarter report. For the three-month stretch ending in September, Neurocrine turned $296 million in revenue into an operating profit of $0.64 per share. On the basis of generally accepted accounting principles (GAAP), however, profits of only $0.23 per share left the market wanting more, and arguably concerned.
- Motley Fool
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript
NBIX earnings call for the period ending September 30, 2021.
© 2022 Yahoo. All rights reserved.
